Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

被引：95

作者：

Beiske, K. ^{[1
]}

Burchill, S. A. ^{[2
]}

Cheung, I. Y. ^{[3
]}

Hiyama, E. ^{[4
]}

Seeger, R. C. ^{[5
]}

Cohn, S. L. ^{[6
]}

Pearson, A. D. J. ^{[7
]}

Matthay, K. K. ^{[8
]}

机构：

[1] Oslo Univ Hosp, Dept Pathol, Rikshosp, N-0027 Oslo, Norway

[2] St James Univ Hosp, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England

[3] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA

[4] Hiroshima Univ, Dept Pediat Surg, Hiroshima 7348551, Japan

[5] Keck Sch Med, Dept Pediat, Los Angeles, CA 90027 USA

[6] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA

[7] Royal Marsden Hosp, Inst Canc Res, Paediat Sect, Sutton SM2 5PT, Surrey, England

[8] Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA

来源：

BRITISH JOURNAL OF CANCER | 2009年 / 100卷 / 10期

关键词：

neuroblastoma; INRG; minimal disease; immunocytology; QRT-PCR; POLYMERASE-CHAIN-REACTION; HYDROXYLASE MESSENGER-RNA; ACUTE LYMPHOBLASTIC-LEUKEMIA; REVERSE TRANSCRIPTION-PCR; STAGE-IV NEUROBLASTOMA; NEURO-BLASTOMA CELLS; REACTION RT-PCR; RESIDUAL DISEASE; TYROSINE-HYDROXYLASE; PERIPHERAL-BLOOD;

D O I：

10.1038/sj.bjc.6605029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group (INRG) Task Force has defined standardised methods for the determination of minimal disease (MD) by immunocytology (IC) and quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) using disialoganglioside G(D2) and tyrosine hydroxylase mRNA respectively. The INRG standard operating procedures (SOPs) define methods for collecting, processing and evaluating bone marrow (BM), peripheral blood (PB) and peripheral blood stem cell harvest by IC and QRT-PCR. Sampling PB and BM is recommended at diagnosis, before and after myeloablative therapy and at the end of treatment. Peripheral blood stem cell products should be analysed at the time of harvest. Performing MD detection according to INRG SOPs will enable laboratories throughout the world to compare their results and thus facilitate quality-controlled multi-centre prospective trials to assess the clinical significance of MD and minimal residual disease in heterogeneous patient groups. British Journal of Cancer (2009) 100, 1627-1637. doi: 10.1038/sj.bjc.6605029 www.bjcancer.com Published online 28 April 2009 (C) 2009 Cancer Research UK

引用

页码：1627 / 1637

页数：11

共 91 条

[81] Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma [J].

Tchirkov, A ;

Paillard, C ;

Halle, P ;

Bernard, F ;

Bordigoni, P ;

Vago, P ;

Deméocq, F ;

Kanold, J .

JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2003, 12 (04) :435-442

[82] RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma [J].

Thomson, B ;

Hawkins, D ;

Felgenhauer, J ;

Radich, JP .

BONE MARROW TRANSPLANTATION, 1999, 24 (05) :527-533

[83] Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastorna cells in blood and bone marrow [J].

Träger, C ;

Kogner, P ;

Lindskog, M ;

Ponthan, F ;

Kullman, A ;

Kågedal, B .

CLINICAL CHEMISTRY, 2003, 49 (01) :104-112

[84] mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis [J].

Trager, Catarina ;

Vernby, Asa ;

Kullman, Anita ;

Ora, Ingrid ;

Kogner, Per ;

Kagedal, Bertil .

INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (12) :2849-2855

[85] Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials [J].

Viprey, V. F. ;

Lastowska, M. A. ;

Corrias, M. V. ;

Swerts, K. ;

Jackson, M. S. ;

Burchill, S. A. .

JOURNAL OF PATHOLOGY, 2008, 216 (02) :245-252

[86] Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: Quality assurance on behalf of SIOPEN-R-NET [J].

Viprey, Virginie F. ;

Corrias, Maria V. ;

Kagedal, Bertil ;

Oltra, Silvestre ;

Swerts, Katrien ;

Vicha, Ales ;

Ladenstein, Ruth ;

Burchill, Susan A. .

EUROPEAN JOURNAL OF CANCER, 2007, 43 (02) :341-350

[87] Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR [J].

Wagner, Lars M. ;

Burger, Rebecca A. ;

Guichard, Sylvie M. ;

Raimondi, Susana C. ;

Santana, Victor M. ;

Furman, Wayne L. ;

Barnette, Phillip ;

Danks, Mary K. .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2006, 28 (10) :635-641

[88] Flow cytometric immunophenotyping test for staging/monitoring neuroblastoma patients [J].

Warzynski, MJ ;

Graham, DM ;

Axtell, RA ;

Higgins, JV ;

Hanmers, YA .

CYTOMETRY, 2002, 50 (06) :298-304

[89] The struggle to detect circulating DNA [J].

Zeerleder, Sacha .

CRITICAL CARE, 2006, 10 (03)

[90]

Zoubek A, 1998, INT J CANCER, V79, P56, DOI 10.1002/(SICI)1097-0215(19980220)79:1<56::AID-IJC11>3.0.CO

← 1 2 3 4 5 6 7 8 9 10 →